Ashworth A - Search Results

1

Future cancer research priorities in the USA: a Lancet Oncology Commission.

Jaffee EM, Dang CV, Agus DB, Alexander BM, Anderson KC, Ashworth A, Barker AD, Bastani R, Bhatia S, Bluestone JA, Brawley O, Butte AJ, Coit DG, Davidson NE, Davis M, DePinho RA, Diasio RB, Draetta G, Frazier AL, Futreal A, Gambhir SS, Ganz PA, Garraway L, Gerson S, Gupta S, Heath J, Hoffman RI, Hudis C, Hughes-Halbert C, Ibrahim R, Jadvar H, Kavanagh B, Kittles R, Le QT, Lippman SM, Mankoff D, Mardis ER, Mayer DK, McMasters K, Meropol NJ, Mitchell B, Naredi P, Ornish D, Pawlik TM, Peppercorn J, Pomper MG, Raghavan D, Ritchie C, Schwarz SW, Sullivan R, Wahl R, Wolchok JD, Wong SL, Yung A. Jaffee EM, et al. Among authors: ashworth a. Lancet Oncol. 2017 Nov;18(11):e653-e706. doi: 10.1016/S1470-2045(17)30698-8. Epub 2017 Oct 31. Lancet Oncol. 2017. PMID: 29208398 Free PMC article. Review.

2

The cancer cell map initiative: defining the hallmark networks of cancer.

Krogan NJ, Lippman S, Agard DA, Ashworth A, Ideker T. Krogan NJ, et al. Among authors: ashworth a. Mol Cell. 2015 May 21;58(4):690-8. doi: 10.1016/j.molcel.2015.05.008. Mol Cell. 2015. PMID: 26000852 Free PMC article. Review.

3

Synthetic lethality as an engine for cancer drug target discovery.

Huang A, Garraway LA, Ashworth A, Weber B. Huang A, et al. Among authors: ashworth a. Nat Rev Drug Discov. 2020 Jan;19(1):23-38. doi: 10.1038/s41573-019-0046-z. Epub 2019 Nov 11. Nat Rev Drug Discov. 2020. PMID: 31712683 Review.

4

Breast cancer molecular profiling with single sample predictors: a retrospective analysis.

Weigelt B, Mackay A, A'hern R, Natrajan R, Tan DS, Dowsett M, Ashworth A, Reis-Filho JS. Weigelt B, et al. Among authors: ashworth a, a hern r. Lancet Oncol. 2010 Apr;11(4):339-49. doi: 10.1016/S1470-2045(10)70008-5. Epub 2010 Feb 22. Lancet Oncol. 2010. PMID: 20181526 Free article.

5

Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007.

Ashworth A, Balkwill F, Bast RC, Berek JS, Kaye A, Boyd JA, Mills G, Weinstein JN, Woolley K, Workman P. Ashworth A, et al. Gynecol Oncol. 2008 Mar;108(3):652-7. doi: 10.1016/j.ygyno.2007.11.014. Epub 2007 Dec 21. Gynecol Oncol. 2008. PMID: 18096210

6

Biology-driven cancer drug development: back to the future.

Lord CJ, Ashworth A. Lord CJ, et al. Among authors: ashworth a. BMC Biol. 2010 Apr 12;8:38. doi: 10.1186/1741-7007-8-38. BMC Biol. 2010. PMID: 20385032 Free PMC article. Review.

7

Familial breast cancer: the first linkage.

Ashworth A. Ashworth A. Lancet Oncol. 2009 Dec;10(12):1212. doi: 10.1016/S1470-2045(09)70235-9. Lancet Oncol. 2009. PMID: 19959078 No abstract available.

8

Translating cancer research into targeted therapeutics.

de Bono JS, Ashworth A. de Bono JS, et al. Among authors: ashworth a. Nature. 2010 Sep 30;467(7315):543-9. doi: 10.1038/nature09339. Nature. 2010. PMID: 20882008

9

Close relatives or distant cousins?

Tutt A, Ashworth A. Tutt A, et al. Among authors: ashworth a. Lancet Oncol. 2003 Oct;4(10):593-4. doi: 10.1016/s1470-2045(03)01217-8. Lancet Oncol. 2003. PMID: 14554235 No abstract available.

10

Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib.

Miller RE, Brough R, Bajrami I, Williamson CT, McDade S, Campbell J, Kigozi A, Rafiq R, Pemberton H, Natrajan R, Joel J, Astley H, Mahoney C, Moore JD, Torrance C, Gordan JD, Webber JT, Levin RS, Shokat KM, Bandyopadhyay S, Lord CJ, Ashworth A. Miller RE, et al. Among authors: ashworth a. Mol Cancer Ther. 2016 Jul;15(7):1472-84. doi: 10.1158/1535-7163.MCT-15-0554. Epub 2016 Jun 30. Mol Cancer Ther. 2016. PMID: 27364904

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

846 results

Search Page

Filters